查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864270

酒精使用障礙市場按藥物類別、治療類型、最終用戶、通路和劑型分類－2025-2032年全球預測

Alcohol Use Disorder Market by Drug Class, Treatment Type, End User, Distribution Channel, Formulation - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，酒精使用障礙市場將成長至 21.7 億美元，複合年成長率為 6.76%。

關鍵市場統計數據
基準年 2024 12.8億美元
預計年份：2025年 13.7億美元
預測年份 2032 21.7億美元
複合年成長率 (%) 6.76%

透過整合式照護路徑、持續藥物治療和數位化服務模式，了解不斷變化的酒精使用障礙治療格局，從而為策略決策提供基礎。

隨著臨床實踐、藥物選擇和治療模式的融合，酒精使用障礙 (AUD) 的治療模式正在迅速發展，以充分滿足日益成長的實證治療需求。長效製劑和多模式療法的進步重塑了治療概念，而數位平台和遠端醫療則拓寬了就醫途徑。因此，AUD 管理體系如今更加強調持續復健、個人化治療組合以及在各種醫療環境中持續參與的策略。

應對治療方法、數位化途徑、支付方獎勵和消除污名化等方面的多方面變革，以重塑酒精使用障礙 (AUD) 的治療服務。

一系列變革正在重塑整個醫療保健系統中酒精使用障礙（AUD）的識別、治療和管理方式。首先，治療方法創新正從傳統的口服藥物擴展到包括注射長效藥物，這些藥物能夠提高患者依從性並降低復發風險，促使臨床醫生重新思考治療方法的啟動和維持策略。伴隨這種多樣化而來的是，人們更加重視多學科方法，將行為療法和藥物療法結合，以增強短期療效和長期康復效果。

分析2025年關稅變化對酒精使用障礙藥物供應鏈區域化、採購調整及生產韌性的影響

2025年美國關稅調整引發了藥品採購、供應鏈成本和製造商籌資策略的新趨勢，並對酒精使用障礙相關產品和通路產生了累積影響。關稅相關的成本壓力迫使製造商重新評估製造地和供應商契約，推動了本地化採購和替代原料供應商的轉變。這些調整影響了口服片劑、發泡製劑和注射劑的前置作業時間和庫存管理，導致製造商更加依賴緩衝庫存並尋求物流合作夥伴的多元化。

提取與營運相關的細分洞察，涵蓋藥物類別、治療方法、臨床環境、通路和製劑策略，以指導商業化和臨床應用。

細緻的市場區隔分析揭示了不同藥物類別、治療方法、醫療機構、通路和劑型所面臨的獨特機會和關鍵執行挑戰。依藥物類別分類，市場包括Acamprosate、Disulfiram和納曲酮。Acamprosate發泡發泡錠和口服片劑可支持不同的依從性和耐受性。Disulfiram主要以口服片劑形式使用，強調監督給藥和行為指導。納曲酮既有注射劑也有口服片劑，使臨床醫生能夠根據患者的依從性風險和合併症情況制定個人化的起始治療策略。這些差異指南臨床定位和通訊，強調起效時間、依從機制和相對耐受性。

區域比較分析突顯了美洲、歐洲、中東和非洲以及亞太地區的支付方複雜性、監管多樣性和數位化准入趨勢。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的治療可近性、監管方式和服務提供模式產生了重大影響。在美洲，整合的醫療保健系統和不斷擴展的遠端醫療基礎設施促進了聯合治療模式和長效注射劑的快速普及。同時，多元化的支付方格局要求靈活的報銷策略和穩健的衛生經濟學，以確保新型療法被納入處方箋目錄並獲得治療方法覆蓋。此外，該地區的跨境供應鏈會根據不斷變化的關稅和物流情況動態調整，從而推動區域採購的調整。

檢驗了企業如何透過結合多元化的產品系列、分銷管道夥伴關係、真實世界數據 (RWE) 生成和供應鏈韌性等策略，來加速治療方案的推廣應用並確保永續的藥物取得。

主要企業層面的發展趨勢集中在產品組合多元化、通路夥伴關係以及對患者支援基礎設施的投資。領先的製造商和專業分銷商正優先考慮整合商業模式，將產品供應與依從性計劃、數位監測工具和臨床醫生教育相結合，以推動產品應用並最佳化治療效果。製藥公司與專業藥房和遠端醫療提供者之間的策略聯盟正在簡化長效療法的應用流程，並支持患者從住院過渡到門診治療期間的護理連續性。

調整支付方夥伴關係，以永續改善醫療服務獲取，優先考慮供應鏈韌性、整合藥物和行為計劃以及數位化醫療服務。

產業領導者應採取雙管齊下的策略，將戰術性營運韌性與長期的臨床和商業性定位相結合。短期內，企業應優先考慮供應鏈多元化，實施雙重採購和區域生產，以降低關稅相關中斷帶來的風險，並確保口服、發泡和注射產品的穩定供應。同時，與醫院藥局、專科藥局和零售合作夥伴協調採購和庫存策略，將確保在急診和維持治療環境中的供應穩定性。

本研究採用混合方法證據綜合分析，結合關鍵相關人員訪談、臨床文獻、監管趨勢和情境建模，以確保研究結果的嚴謹性和可操作性。

本研究途徑採用混合研究方法，將質性一手研究與同儕審查文獻、臨床指引、監理通訊和已發布的政策聲明等二手資料綜合分析結合。一手數據包括對住院和門診臨床醫生、醫院和專科藥房的採購人員以及生產商和經銷商的高管進行的結構化訪談。這些訪談提供了關於產品推廣促進因素、管理障礙以及製劑和通路選擇對營運影響的實地觀點。

整合治療方法創新、不斷發展的給藥方式和運作韌性之間的相互作用，以確定永續臨床和商業性影響的優先事項。

治療方法、服務途徑和政策方面的融合趨勢，正為酒精使用障礙照護領域的相關人員創造一個關鍵時刻。製劑技術的創新和綜合治療方法的進步，拓展了臨床醫生可用的工具箱；而數位化平台和不斷演進的報銷模式，則為維持患者參與度和展現價值開闢了新的途徑。供應鍊和關稅壓力凸顯了營運韌性的重要性，同時也獎勵對區域能力和採購多元化進行策略性投資，從而實現長期穩定。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 透過將數位療法和遠端醫療解決方案整合到實證酒精使用障礙治療中，改善患者療效
  • 人工智慧驅動的預測分析在行動醫療應用中的日益普及，正在推動個人化酒精渴求管理和復發預防。
  • 長效注射用納曲酮和其他先進的緩釋性藥物的出現，提高了酒精使用障礙治療的依從性。
  • 遠距精神病學平台快速發展，為酒精使用障礙患者提供遠端諮詢和藥物管理。
  • 利用遺傳和神經生物學標記開發精準醫療策略，以實現酒精使用障礙的個人化藥物治療。
  • 認知行為諮商和虛擬實境暴露療法正日益融合，以更有效地解決酒精使用障礙的誘因。
  • 擴大由雇主主導的數位介入計畫規模，這些計畫將遠端監測和同儕支持納入酒精使用障礙復健治療中。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的酒精使用疾患市場

  • Acamprosate
    • 發泡
    • 口服錠劑
  • Disulfiram
    • 口服錠劑
  • 納曲酮
    • 注射
    • 口服錠劑

9. 依治療類型分類的酒精使用疾患市場

  • 行為療法
    • 認知行為療法
    • 家庭治療
    • 動機增強療法
  • 聯合療法
    • 藥物輔助認知行為療法
    • 藥物輔助的動機增強療法
  • 藥物治療
    • 注射藥物
    • 口服藥物

10. 按最終用戶分類的酒精使用障礙市場

  • 居家醫療
    • 家庭到府醫療服務
    • 遠端醫療
  • 醫院
    • 私立醫院
    • 公立醫院
  • 復健中心
    • 住院病人
    • 門診
  • 專科診所
    • 酒精成癮康復診所
    • 精神病診所

11. 按分銷管道分類的酒精使用障礙市場

  • 醫院藥房
    • 私立醫院藥房
    • 公立醫院藥房
  • 網路藥房
    • 電子商務網站
    • 行動應用
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房
  • 專科藥房
    • 酒精使用障礙（AUD）專科藥房
    • 普通藥房和專科藥房

12. 依配方分類的酒精使用障礙市場

  • 分散片
  • 發泡
  • 注射
    • 肌肉內注射
    • 靜脈注射
    • 皮下注射
  • 口服錠劑
    • 立即生效
    • 緩釋性

13. 各地區酒精使用疾患市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 按群體分類的酒精使用障礙市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國酒精使用疾患市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Alkermes plc
    • H. Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma Ltd.
    • Lupin Limited
    • Cipla Limited
Product Code: MRR-351BAD503A27

The Alcohol Use Disorder Market is projected to grow by USD 2.17 billion at a CAGR of 6.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.28 billion
Estimated Year [2025] USD 1.37 billion
Forecast Year [2032] USD 2.17 billion
CAGR (%) 6.76%

Framing the evolving Alcohol Use Disorder treatment landscape with integrated care pathways, long-acting pharmacotherapies, and digital access models to inform strategic decisions

The landscape of Alcohol Use Disorder (AUD) care is rapidly evolving as clinical practice, pharmacologic options, and delivery models converge to better meet the growing demand for evidence-based treatment. Advances in long-acting formulations and multimodal approaches have reframed treatment conversations, while digital platforms and telehealth have expanded pathways to care. Consequently, the continuum of AUD management now emphasizes sustained recovery, individualized therapeutic combinations, and durable engagement strategies across diverse care settings.

Clinicians and health system leaders are increasingly prioritizing integrated care pathways that combine behavioral interventions with pharmacotherapy, and payers are recalibrating coverage criteria in response to outcomes data and cost-of-care considerations. Meanwhile, regulatory movements and public health campaigns are shaping perceptions and access, underscoring the importance of adaptable clinical protocols and supply-chain resilience. This introduction outlines the main forces reshaping treatment paradigms, highlights the intersection of technology and therapeutics, and situates stakeholders to capitalize on actionable insights emerging across clinical, regulatory, and commercial domains.

Navigating multipronged changes in therapy modalities, digital access pathways, payer incentives, and stigma reduction that are reshaping Alcohol Use Disorder care delivery

A series of transformative shifts is redefining how AUD is identified, treated, and managed across healthcare systems. First, therapeutic innovation has expanded beyond traditional oral dosing to include injectable long-acting agents that improve adherence and reduce relapse risk, prompting clinicians to reconsider initiation and maintenance strategies. This therapeutic diversification is accompanied by renewed emphasis on combination approaches that align behavioral therapies with pharmacotherapies to bolster both short-term engagement and long-term recovery trajectories.

Concurrently, digital health solutions are changing patient touchpoints. Telehealth and remote monitoring enable continuity of care for patients in rural or underserved areas and facilitate stepped-care models that move patients between intensity levels according to real-time clinical signals. These digital pathways also create opportunities for novel adherence interventions and remote behavioral coaching that complement in-person services. Meanwhile, payer and regulatory environments are responding to these innovations with more nuanced coverage determinations and value-based contracting pilots that prioritize measurable outcomes over service volume.

Finally, public and provider awareness campaigns have shifted stigma-related barriers to care, increasing screening rates and early intervention. Collectively, these changes generate a more patient-centric, outcomes-oriented ecosystem that rewards integrated care, device-enabled adherence, and evidence-based combinations of behavioral and pharmacologic modalities. Stakeholders who align product development, distribution, and clinical training with these shifts are positioned to lead in both clinical impact and commercial performance.

Analyzing how 2025 tariff shifts catalyzed supply chain regionalization, procurement adaptations, and manufacturing resilience for Alcohol Use Disorder therapies

United States tariff adjustments in 2025 introduced new dynamics into pharmaceutical procurement, supply chain costs, and manufacturer sourcing strategies, with cumulative consequences for AUD-related products and distribution channels. Tariff-related cost pressures compelled manufacturers to reassess manufacturing footprints and supplier contracts, prompting shifts toward regionalized sourcing and alternative raw material suppliers. These adjustments influenced lead times and inventory practices for oral tablets, effervescent formulations, and injectable therapeutics, encouraging greater reliance on buffer inventories and diversified logistics partners.

In turn, hospital pharmacies, specialty pharmacies, and retail distributors adjusted procurement cadence to mitigate exposure to pricing volatility. Some providers increased contract durations with preferred suppliers to lock in price stability, while others explored consignment and group-purchasing arrangements to preserve access without disproportionately transferring costs to patients. These procurement adaptations affected the availability of both immediate-release and sustained-release oral formulations as well as injectable intramuscular and subcutaneous options, with downstream implications for initiation protocols and adherence programs.

Additionally, the tariff environment accelerated conversations around domestic manufacturing incentives and reshored capacity for critical excipients and finished-dose forms. Policymakers and industry leaders engaged in dialogue about incentives to stabilize supply chains and reduce systemic vulnerability. As a result, strategic planning for commercialization now routinely incorporates tariff scenario modeling, dual-sourcing strategies, and cost-pass-through considerations to maintain therapeutic continuity for patients while preserving financial viability for manufacturers and distributors.

Distilling operationally relevant segmentation insights across drug classes, treatment modalities, care settings, distribution channels, and formulation strategies to guide commercialization and clinical adoption

A nuanced segmentation analysis reveals distinct opportunities and execution imperatives across drug classes, treatment modalities, care settings, distribution channels, and formulation types. Within drug classes, the market includes acamprosate, disulfiram, and naltrexone; acamprosate's effervescent and oral tablet presentations support different adherence and tolerability profiles, disulfiram is primarily deployed in oral tablet form where supervised administration and behavioral frameworks are emphasized, and naltrexone is available both as injectables and oral tablets, enabling clinicians to tailor initiation strategies based on patient adherence risk and comorbidity profiles. These distinctions inform clinical positioning and messaging that emphasize onset of effect, adherence mechanisms, and comparative tolerability.

When examining treatment types, behavioral therapy, combined therapy, and pharmacotherapy create complementary pathways for intervention. Behavioral therapy encompasses cognitive behavioral therapy, family therapy, and motivational enhancement therapy, each addressing different psychosocial drivers of substance use and recovery readiness. Combined therapy-such as cognitive behavioral therapy with pharmacotherapy or motivational enhancement therapy with pharmacotherapy-integrates pharmacologic support with structured psychosocial interventions to enhance engagement and outcomes. Pharmacotherapy itself bifurcates into injectable and oral drugs, which present divergent needs in terms of dispensing, monitoring, and reimbursement practices. Understanding the interplay between these treatment paradigms is critical for designing integrated care protocols and training programs for multidisciplinary teams.

End-user segmentation further differentiates operational requirements and access patterns. Home healthcare, hospitals, rehabilitation centers, and specialty clinics each demand tailored service models. Home healthcare services leverage home visits and telehealth to extend continuity for patients who prefer community-based care, hospitals-both private and public-serve as high-acuity initiation points where inpatient stabilization and transitioning to outpatient care are coordinated, rehabilitation centers operate across inpatient and outpatient modalities to support structured recovery programs, and specialty clinics, including alcohol rehabilitation and psychiatric clinics, focus on longitudinal follow-up and complex case management. These distinctions affect referral pathways, reimbursement mechanisms, staffing models, and the design of adherence support services.

Distribution channel segmentation highlights the importance of channel-specific strategies. Hospital pharmacies-split between private and public institutions-must balance formulary access and acute-care needs, online pharmacies accessed via e-commerce websites and mobile apps facilitate convenience and discreet delivery for maintenance therapy, retail pharmacies comprised of chain and independent outlets provide widespread dispensing capability and patient counseling touchpoints, and specialty pharmacies, both addiction-focused and general, offer medication therapy management and care coordination for complex cases. Tailoring supply chain logistics, patient education, and specialty services to these channels enhances access and retention.

Finally, formulation segmentation-dispersible tablet, effervescent tablet, injectable, and oral tablet-demands careful commercialization choices. Injectable forms include intramuscular, intravenous, and subcutaneous routes that vary in administration setting and clinical workflow, while oral tablets encompass immediate-release and sustained-release profiles that influence dosing frequency and adherence support needs. Bringing these formulation insights together enables manufacturers, payers, and providers to align product development, reimbursement strategies, and patient support programs with real-world clinical utilization patterns and operational constraints.

Comparative regional dynamics revealing payer complexity, regulatory heterogeneity, and digital-enabled access trajectories across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence treatment access, regulatory approaches, and service delivery models across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, integrated health systems and expanding telehealth infrastructure have supported rapid adoption of combined therapy models and long-acting injectables, while diverse payer landscapes necessitate flexible reimbursement strategies and robust health economics narratives to secure formulary placement and coverage for newer modalities. Cross-border supply chains in the region also respond dynamically to tariff and logistics changes, prompting localized procurement adjustments.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and variable health system capacities create both challenges and targeted opportunities. High-income markets within this region often lead with structured national treatment guidelines and strong specialty clinic networks, supporting adoption of evidence-backed combination treatments and specialty pharmacy services. Conversely, lower-resource settings emphasize task-shifting, community-based interventions, and scalable behavioral programs, which present opportunities to leverage telehealth and simplified pharmacotherapy regimens that are easy to deploy at scale.

The Asia-Pacific region exhibits a mix of rapid urbanization, growing healthcare infrastructure investment, and distinct cultural attitudes toward substance use that shape demand and care pathways. Increasing investments in specialty clinics, expanding private hospital networks, and mobile health penetration create fertile ground for novel distribution channels such as mobile app-enabled pharmacy services and hybrid home healthcare models. Across regions, supply-chain resilience, regulatory alignment, and culturally tailored patient engagement approaches emerge as cross-cutting enablers for successful deployment of AUD therapeutics and integrated care services.

Examining company strategies that combine diversified portfolios, channel partnerships, real-world evidence generation, and supply-chain resilience to drive uptake and sustain access

Key company-level dynamics center on portfolio diversification, channel partnerships, and investments in patient support infrastructure. Leading manufacturers and specialty distributors increasingly prioritize integrated commercial models that pair product availability with adherence programs, digital monitoring tools, and clinician education to accelerate uptake and optimize outcomes. Strategic partnerships between pharmaceutical firms and specialty pharmacies or telehealth providers enable streamlined initiation processes for long-acting therapies and support continuity of care across inpatient and outpatient transitions.

Additionally, contract strategies and value-based arrangements are gaining prominence as payers seek measurable outcome improvements and cost containment. Companies that can demonstrate robust real-world evidence and offer bundled services-such as medication management, tele-coaching, and outcome tracking-are better positioned to negotiate favorable coverage terms. Supply-chain investments, including dual-sourcing, regional manufacturing partnerships, and contingency inventories, have become integral to preserving product availability and mitigating tariff-related disruptions.

Finally, companies that invest in clinician training, stigma-reduction campaigns, and culturally sensitive patient materials tend to secure stronger prescriber relationships and higher initiation rates. By aligning commercial efforts with evidence-based clinical practices and responsive distribution strategies, market participants can drive both clinical impact and sustainable business performance in a complex and rapidly evolving therapeutic area.

Prioritize supply-chain resilience, integrated pharmacotherapy and behavioral programs, and digital-enabled care while aligning payer partnerships for durable access gains

Industry leaders should adopt a dual-focus strategy that combines tactical operational resilience with long-term clinical and commercial positioning. In the near term, firms must prioritize supply-chain diversification, implementing dual-sourcing and regional manufacturing arrangements to reduce exposure to tariff-driven disruptions and ensure consistent access to oral, effervescent, and injectable formulations. At the same time, aligning procurement and inventory strategies with hospital pharmacies, specialty pharmacies, and retail partners will safeguard availability across both acute and maintenance settings.

Concurrently, organizations should invest in integrated care enablement by scaling programs that combine pharmacotherapy with evidence-based behavioral therapies. Embedding cognitive behavioral therapy, family therapy, and motivational enhancement therapy into care pathways alongside pharmacologic options encourages adherence and supports sustained recovery. Companies can accelerate adoption by funding clinician education, supporting multidisciplinary care teams, and offering reimbursement-ready value propositions grounded in real-world outcomes.

To capture long-term value, leaders must also prioritize digital engagement and home-based care models. Telehealth, mobile adherence tools, and remote monitoring expand reach and reduce barriers to care, especially when paired with specialty pharmacy support and telepharmacy services. Finally, fostering payer partnerships through transparent outcomes measurement and pilot value-based agreements will facilitate broader access; by demonstrating measurable improvements in clinical and economic endpoints, organizations can de-risk coverage decisions and create a favorable environment for innovative therapies and service bundles.

Employing a mixed-methods evidence synthesis that triangulates primary stakeholder interviews, clinical literature, regulatory signals, and scenario modeling to ensure actionable rigor

The research approach combined a mixed-methods design that integrated primary qualitative engagement with secondary synthesis of peer-reviewed literature, clinical guidelines, regulatory communications, and publicly available policy statements. Primary inputs included structured interviews with clinicians across inpatient and outpatient settings, procurement leaders at hospital and specialty pharmacies, and executives from manufacturers and distributors. These engagements provided frontline perspectives on adoption drivers, administrative barriers, and the operational implications of formulation and channel choices.

Secondary analysis synthesized clinical trial literature, guideline updates, and health system policy changes to contextualize primary insights and validate observed trends. The methodology emphasized triangulation: qualitative findings were cross-referenced with published clinical evidence and regulatory developments to strengthen analytic rigor. Scenario analysis simulated the operational impacts of supply-chain disruptions and tariff shifts, while thematic coding of interview transcripts identified recurring barriers and enablers related to initiation, adherence, and reimbursement.

Throughout, emphasis was placed on transparency and reproducibility. Data sources were documented, stakeholder selection criteria were specified to ensure representativeness across care settings and regions, and analytic steps were recorded to permit replication. This methodology supports defensible conclusions and actionable recommendations while reflecting the multifaceted realities of clinical practice, procurement, and commercialization in AUD care.

Synthesize the interplay between therapeutic innovation, delivery evolution, and operational resilience to define priorities for sustainable clinical and commercial impact

The converging trends in therapeutics, delivery channels, and policy create a decisive moment for stakeholders involved in Alcohol Use Disorder care. Innovations in formulation and integrated treatment approaches are expanding the toolkit available to clinicians, while digital platforms and evolving reimbursement paradigms create new pathways to sustain engagement and demonstrate value. Supply-chain and tariff pressures underscore the importance of operational resilience, yet they also incentivize strategic investments in regional capacity and diversified sourcing that can yield long-term stability.

In summary, success will hinge on coordinated action across product development, distribution, clinical training, and payer engagement. Stakeholders who proactively design integrated care models, invest in adherence-enabling technologies, and cultivate payer relationships anchored in real-world outcomes will be best positioned to improve patient trajectories and secure sustainable commercial performance. The pathway forward requires balanced attention to immediate operational risks and long-term clinical and economic value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of digital therapeutics and telehealth solutions in evidence-based alcohol use disorder treatment to improve patient outcomes
  • 5.2. Rising adoption of AI-driven predictive analytics in mobile health apps to personalize alcohol craving management and relapse prevention
  • 5.3. Emergence of long-acting injectable naltrexone and other advanced extended-release medications to enhance adherence in alcohol use disorder therapy
  • 5.4. Rapid growth of telepsychiatry platforms enabling remote counseling and medication management for individuals with alcohol use disorder
  • 5.5. Development of precision medicine strategies leveraging genetic and neurobiological biomarkers to tailor pharmacotherapy in alcohol use disorder
  • 5.6. Increasing integration of virtual reality exposure therapy with cognitive behavioral counseling to address alcohol use disorder triggers more effectively
  • 5.7. Expansion of employer-sponsored digital intervention programs incorporating remote monitoring and peer support for alcohol use disorder recovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Alcohol Use Disorder Market, by Drug Class

  • 8.1. Acamprosate
    • 8.1.1. Effervescent Tablet
    • 8.1.2. Oral Tablet
  • 8.2. Disulfiram
    • 8.2.1. Oral Tablet
  • 8.3. Naltrexone
    • 8.3.1. Injectable
    • 8.3.2. Oral Tablet

9. Alcohol Use Disorder Market, by Treatment Type

  • 9.1. Behavioral Therapy
    • 9.1.1. Cognitive Behavioral Therapy
    • 9.1.2. Family Therapy
    • 9.1.3. Motivational Enhancement Therapy
  • 9.2. Combined Therapy
    • 9.2.1. Cbt With Pharmacotherapy
    • 9.2.2. Met With Pharmacotherapy
  • 9.3. Pharmacotherapy
    • 9.3.1. Injectable Drugs
    • 9.3.2. Oral Drugs

10. Alcohol Use Disorder Market, by End User

  • 10.1. Home Healthcare
    • 10.1.1. Home Visits
    • 10.1.2. Telehealth
  • 10.2. Hospitals
    • 10.2.1. Private Hospitals
    • 10.2.2. Public Hospitals
  • 10.3. Rehabilitation Centers
    • 10.3.1. Inpatient
    • 10.3.2. Outpatient
  • 10.4. Specialty Clinics
    • 10.4.1. Alcohol Rehabilitation Clinics
    • 10.4.2. Psychiatric Clinics

11. Alcohol Use Disorder Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
    • 11.1.1. Private Hospital Pharmacies
    • 11.1.2. Public Hospital Pharmacies
  • 11.2. Online Pharmacies
    • 11.2.1. E-Commerce Websites
    • 11.2.2. Mobile Apps
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies
  • 11.4. Specialty Pharmacies
    • 11.4.1. Aud Specialty Pharmacies
    • 11.4.2. General Specialty Pharmacies

12. Alcohol Use Disorder Market, by Formulation

  • 12.1. Dispersible Tablet
  • 12.2. Effervescent Tablet
  • 12.3. Injectable
    • 12.3.1. Intramuscular
    • 12.3.2. Intravenous
    • 12.3.3. Subcutaneous
  • 12.4. Oral Tablet
    • 12.4.1. Immediate Release
    • 12.4.2. Sustained Release

13. Alcohol Use Disorder Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Alcohol Use Disorder Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Alcohol Use Disorder Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Alkermes plc
    • 16.3.2. H. Lundbeck A/S
    • 16.3.3. Teva Pharmaceutical Industries Ltd.
    • 16.3.4. Viatris Inc.
    • 16.3.5. Sandoz International GmbH
    • 16.3.6. Dr. Reddy's Laboratories Ltd.
    • 16.3.7. Sun Pharmaceutical Industries Ltd.
    • 16.3.8. Aurobindo Pharma Ltd.
    • 16.3.9. Lupin Limited
    • 16.3.10. Cipla Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ALCOHOL USE DISORDER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ALCOHOL USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALCOHOL USE DISORDER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOTIVATIONAL ENHANCEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY COMBINED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CBT WITH PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MET WITH PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ORAL DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOME VISITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY TELEHEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ALCOHOL REHABILITATION CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PSYCHIATRIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PRIVATE HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY PUBLIC HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY E-COMMERCE WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY MOBILE APPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY AUD SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY GENERAL SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY DISPERSIBLE TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY EFFERVESCENT TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL ALCOHOL USE DISORDER